Pharmacogenetics of non-steroidal anti-inflammatory drugs: existing problems for clinical practice

NSAIDs are the most commonly used drugs in clinical practice for pain relief in various diseases. To date, considerable scientific material has been accumulated on the pharmacogenetics of NSAIDs and the role of genetic factors that can influence the pharmacokinetics and pharmacodynamics of drugs, changing the efficacy and toxicity profile. The most clinically significant changes in pharmacokinetics in carriers of slow alleles of CYP2C9*3 have been identified for celecoxib and flurbiprofen, which determines the need for testing and lowering of drug doses. Studies were carried out to study the role of polymorphism of the metabolizing enzymes CYP2C9, CYP2C8, UGT in the development of gastrotoxicity and gastrointestinal bleeding during application NSAIDs, as well as diclofenac’s hepatotoxicity. The association of «slow» alleles CYP2C8*3 and CYP2C9*2,*3 with the risk of gastrointestinal bleeding associated with NSAID use, which are substrates of CYP2C9 and CYP2C8, is shown. The effect of variants of alleles PTGS1 (gene COX-1) and PTGS2 (gene COX-2) on pharmacodynamics, efficacy and toxicity of NSAIDs, in particular, the severity of the analgesic effect and cardiotoxicity of the drugs, was studied. In this way, pharmacogenetic predictors of adverse effects that patients can experience, and the need for dose adjustment based on the patient’s genotype, or individualizing the choice of alternative NSAIDs to increase the effectiveness of analgesia, have been determined.

1. Clinical guidelines for the rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice. Sovremennaya Revmatologia. 2015; 1: 4-23. (In Russ).

2. McNamara D. Gastrooesophageal reflux disease and ulcer disease in Europe: NSAIDrelated gastroduodenal pathology. The Burden of Gastrointestinal Diseases in Europe. 2004: 31–6.

3. Zhou S.F., Zhou Z.W., Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology. 2010; 278(2): 165-88.

4. Wang B., Wang J., Huang S.Q., Su H.H., Zhou S.F. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab. 2009; 10(7): 781-834.

5. Rodrigues A.D. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab. Dispos. 2005; 33(11): 1567-75.

6. Rollason V., Samer C.F., Daali Y., Desmeules J.A. Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti-Inflammatory Drugs: A Review. Current Drug Metabolism. 2014; 15: 326-43.

7. Agúndez J.A.G., García-Martín E., Martínez C. Genetically based impair-ment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009; 5(6): 607-20.

8. Yiannakopoulou E. Pharmacogenomics of acetylsalicylic acid and other nonsteroidal antiinflammatory agents: clinical implications. Eur J Clin Pharmacol. 2013; 69: 1369–73.

9. Stingl J.C., Bartels H., Viviani R., Lehmann M.L., Brockmoller J. Relevance of UDPglucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacol. Ther. 2014;141(1): 92-116.

10. Wyatt J.E., Pettit W.L., Harirforoosh S. Pharmacogenetics of nonsteroidal anti-inflammatory drugs. Pharmacogenomics J. 2012; 12: 462–7.

11. Table of Pharmacogenomic Biomarkers in Drug Labels. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm (Accessed October 29, 2013).

12. Martínez C., Blanco G., Ladero J.M., GarcíaMartín E., Taxonera C., Gamito F.G., Diaz-Rubio M., Agúndez J.A.G. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004; 141: 205–8.

13. Pilotto A., Seripa D., Franceschi M., Scarcelli C., Colaizzo D., Grandone E., Niro V., Andriulli A., Leandro G., Di Mario F., Dallapiccola B. Genetic susceptibility to nonsteroidal antiinflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007; 133(2): 465-71.

14. Blanco G., Martínez C., Ladero J.M., GarciaMartin E., Taxonera C., Gamito F.G., Diaz-Rubio M., Agundez J.A. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics. 2008; 18(1): 37-43.

15. Obzherina A.Yu., Sychev D.A., Muravyova Yu.V., Ignatiev I.V., Dmitriev V.A., Kukes V.G. CYP2C9 polymorphism: a new risk factor for the development of gastrointestinal complications following the use of nonsteroidal anti-inflammatory drugs. Klinicheskaya Farmakologia i Farmakoekonomika. 2009; 2 (5): 20-5. (In Russ).

16. Lampe J.W., Bigler J., Horner N.K., Potter J.D. UDPglucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics. 1999; 9(3): 341- 9.

17. van Oijen M.G., Koetsier M.I., Laheij R.J., Roelofs H.M., te Morsche R.H., Peters W.H., Verheugt F.W., Jansen J.B., Drenth J.P. Genetic polymorphisms in UDP-glucuronosyltransferase 1A6 are not associated with NSAIDs-related peptic ulcer haemorrhage. Drug Metab. Lett. 2009; 3(3): 199-204.

18. Daly A.K., Aithal G.P., Leathart J.B., Swainsbury R.A., Dang T.S., Day C.P. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007; 132: 272-81.

19. Ulrich C.M., Bigler J., Sibert J., Greene E.A., Sparks R., Carlson C.S., Potter J.D. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum. Mutat. 2002; 20(5): 409-10.

20. van Oijen M.G., Laheij R.J., Koetsier M., de Kleine E., Te Morsche R.H., van Kerkhoven L.A., Jansen J.B., Drenth J.P. Effect of a specific cyclooxygenase-gene polymorphism (A-842G/ C50T) on the occurrence of peptic ulcer hemorrhage. Dig. Dis. Sci. 2006; 51(12): 2348-52.

21. St Germaine C.G., Bogaty P., Boyer L., Hanley J., Engert J.C., Brophy J.M. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. Am. J. Cardiol. 2010; 105(12): 1740-5.

22. Nagao M., Sato Y., Yamauchi A. A meta-analysis of PTGS1 and PTGS2 polymorphisms and NSAID intake on the risk of developing cancer. PLoS ONE. 2013; 8(8): e71126.

23. Thorn C.F., Grosser T., Klein T.E., Altman R.B. PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenet. Genomics. 2011; 21(9): 607-13.

24. Lee Y.S., Kim H., Wu T.X., Wang X.M., Dionne R.A. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin. Pharmacol. Ther. 2006; 7(5): 407-18.